The TRINITI-1 study which examines triplet therapy of hormone receptor positive (HR+), HER2- advanced breast cancer with ribociclib (CDK4/6 inhibition), RAD001 (mTOR inhibition) and exemestane (endocrine therapy) showed clinical benefit in a preliminary analysis in 95 patients (Bardia et al. 2019). This evidence concerns the gene ERBB2 and breast cancer.